Now Available: Portugal Pharmaceuticals & Healthcare Report Q3 2013
Portugal continues to struggle in the face of continued austerity measures, cuts and the financial obligations of its EU, ECB and IMF economic adjustment package, approved in May 2011. Its prospects deteriorated further in Q213, following the publication of PhRMA's Special 301 Submission report for 2013. This has called for Portugal to be placed on the Priority Watch List, because of concerns such as that patent protection is not as robust as it should be, that pharmaceutical firms are finding...
View full press release